HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Alcohol withdrawal hallucinosis — Clinical Guidelines

Overview

Alcohol withdrawal hallucinosis is a severe manifestation of alcohol withdrawal syndrome characterized by visual, auditory, or tactile hallucinations, often occurring within the broader context of alcohol withdrawal symptoms but typically without the full-blown delirium seen in alcohol withdrawal delirium (AWD). 4

Diagnosis

Key Diagnostic Criteria: Presence of hallucinations (visual, auditory, tactile) without significant cognitive impairment or fluctuating consciousness.

Recommended Tests: Clinical assessment using tools like the Clinical Institute Withdrawal Assessment for Alcohol - Revised (CIWA-Ar) to evaluate severity and progression. 5

Grading: Severity grading can be assessed using CIWA-Ar scores, though specific thresholds for hallucinosis are not universally defined. 5

Management

First-Line Treatments:

- Benzodiazepines (BZDs): Recommended as first-line therapy due to their efficacy in managing withdrawal symptoms and preventing complications. 4

Adjunctive Treatments:

- Phenobarbital: Used as an alternative or adjunct, particularly in cases where BZDs are ineffective or contraindicated. Evidence suggests potential benefits but with concerns over adverse events. 1 2 3 - Dexmedetomidine: Added to BZD-based sedation in refractory cases of AWD, showing promise with no observed adverse events in small series, though further studies are needed. 7

Special Populations

Elderly: Phenobarbital use requires caution due to increased risk of adverse events such as over-sedation and respiratory depression. 2

Comorbidities: Choice of medication should consider comorbidities; phenobarbital may be considered in patients with inadequate response to BZDs but requires careful monitoring. 3

Key Recommendations

Primary Treatment with Benzodiazepines: Use benzodiazepines as the first-line treatment for alcohol withdrawal syndrome, including cases with hallucinations, due to robust evidence supporting their efficacy and safety profile. (Evidence: Strong 4)

Consider Phenobarbital as an Alternative: In cases where benzodiazepines are ineffective or contraindicated, phenobarbital can be considered, though close monitoring for adverse events is essential. (Evidence: Moderate 1 2 3)

Monitor with CIWA-Ar: Utilize the CIWA-Ar tool for objective assessment and monitoring of symptom progression and treatment efficacy in patients with alcohol withdrawal syndrome. (Evidence: Moderate 5)

References

1 Lee CM, Dillon DG, Tahir PM, Murphy CE. Phenobarbital treatment of alcohol withdrawal in the emergency department: A systematic review and meta-analysis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2024. link 2 Ronan MV, Ganatra RB, Saukkonen J. Establishing the safety of phenobarbital treatment of alcohol withdrawal syndrome on general medical wards: A retrospective cohort study. Alcohol (Fayetteville, N.Y.) 2024. link 3 Nishimura Y, Choi H, Colgan B, Kistler H, Mercado F. Current evidence and clinical utility of phenobarbital for alcohol withdrawal syndrome. European journal of internal medicine 2023. link 4 Mierzejewski P, Bieńkowski P, Jakubczyk A, Samochowiec J, Silczuk A, Wojnar M. Pharmacotherapy of alcohol withdrawal syndromes - Recommendations of the Polish Psychiatric Association and the Pharmacotherapy Section of the Polish Society for Addiction Research. Psychiatria polska 2022. link 5 Pribék IK, Kovács I, Kádár BK, Kovács CS, Richman MJ, Janka Z et al.. Evaluation of the course and treatment of Alcohol Withdrawal Syndrome with the Clinical Institute Withdrawal Assessment for Alcohol - Revised: A systematic review-based meta-analysis. Drug and alcohol dependence 2021. link 6 Eads V, Maruzzella G. The Clinical Nurse as an Agent of Change. Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses 2016. link 7 Tolonen J, Rossinen J, Alho H, Harjola VP. Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. European journal of emergency medicine : official journal of the European Society for Emergency Medicine 2013. link

Alcohol withdrawal hallucinosis